NCT05953584 - A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

September 20, 2027

Study Completion Date

September 20, 2027

Conditions

Sickle Cell Disease

Interventions

DRUG

Etavopivat

Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.

DRUG

Hydroxyurea

Participants will receive a stable dose of HU.

Trial Locations (9)

RECRUITING

Sultan Qaboos University Hospital, Muscat

RECRUITING

Lagos University Teaching Hospital, Lagos, Lagos

RECRUITING

All India Institute of Medical Sciences-Delhi, Delhi

RECRUITING

University of Ibadan, University College Hospital, Ibadan

RECRUITING

Nirmal Hospital Pvt. Ltd., Gujarat

RECRUITING

Suretech Hospital and Research Centre Ltd., Maharashtra

NOT_YET_RECRUITING

Indira Gandhi Government Medical College & Hospital, Nagpur

RECRUITING

All India Institute of Medical Sciences (AIIMS), Raipur, Raipur

RECRUITING

Aminu Kano Teaching Hospital (AKTH), Tarauni